Pregabalin Capsule
Product Images NDC 71335-9671

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-9671). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713359671)

Pregabalin Capsules, USP 225 mg oral dosage form with NDC 71335-9671-1. This repackaged product by Bryant Ranch Prepack, Inc. comes in a bottle containing 30 capsules. The label includes storage instructions and a caution to keep drugs out of reach of children. The BRP Pharmaceuticals logo is visible.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Four lines represent different dosages of Pregabalin (200 mg, 100 mg, 25 mg three times a day) and placebo, illustrating patient response rates across varying pain improvement percentages.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day with a placebo, depicting higher patient improvement percentages for Pregabalin across increasing pain improvement thresholds.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 300 mg, 150 mg, and 75 mg taken twice a day, compared to placebo. The graph shows four lines representing each treatment group, with improvement percentages and pain reduction on the axes.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percentage of patients improved at various levels of percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percent of patients improved from 0 to 100%. Pregabalin 200 mg consistently shows higher patient improvement compared to the 100 mg dose and placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 100 mg three times a day, Pregabalin at 50 mg three times a day, and placebo. The graph shows three separate lines identifying each treatment's effectiveness in pain improvement over a range from 0 to 100 percent improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) for Pregabalin doses versus placebo across two studies (E1 and E3). Study E1 shows responder rates increasing from placebo to 600 mg/day under BID dosing, with rates from 14% to 51%. Study E3 compares placebo, 300 mg/day BID, and 600 mg/day TID dosing, showing rates from 9% to 49%. Statistical significance versus placebo is indicated for certain doses.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting median percent change from baseline in seizure reduction versus dose in mg/day for four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID. The graph shows increasing seizure reduction with higher doses up to 600 mg/day, with significant p-values indicated for various data points. The x-axis represents dose in mg/day, and the y-axis represents seizure reduction percentage.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, illustrating patient response to varying doses of Pregabalin and placebo in terms of pain improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line chart comparing the estimated percentage of subjects without LTR over time in days between Pregabalin and Placebo groups. The y-axis shows the estimated percentage from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group is represented by a solid line, showing a higher percentage of subjects without LTR over time compared to the placebo group, represented by a dashed line.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12, showing Pregabalin versus Placebo. The x-axis represents percent improvement from baseline up to 100%, and the y-axis shows the percent of subjects improved, also up to 100%. Pregabalin shows a higher percent of subjects improved across the timeline compared to Placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved over a range of improvement percentages from baseline to week 16 BOCF. The graph includes two lines: one solid line for Pregabalin and one dashed line for placebo, showing Pregabalin generally having a higher percent of subjects improved across the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A text panel displaying the formula for calculating creatinine clearance (CLcr) based on a patient's age, weight, and serum creatinine levels, including an adjustment factor for female patients. This information is often used in dosing considerations for Pregabalin capsules 225 mg by Bryant Ranch Prepack.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, showing its skeletal formula with functional groups including an amino group (NH2) and a carboxylic acid group (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.